Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Tricuspid regurgitation progresses in line with right ventricular remodelling and increasing pulmonary artery systolic pressure in patients with pulmonary arterial hypertension, research shows.
Research suggests that regulatory T cells may play a part in all subtypes of pulmonary arterial hypertension.
Levels of galectin-3 are elevated in patients with pulmonary arterial hypertension and correlate with disease severity, research shows.
A tissue phase mapping study shows that left ventricular function is abnormal in patients with pulmonary arterial hypertension and is linked to clinical outcomes.
Sildenafil may be better given to pulmonary arterial hypertension patients in combination with ambrisentan than with bosentan, study findings suggest.
Mutations in the bone morphogenetic protein receptor type II gene affect not only the risk of developing pulmonary arterial hypertension but also the severity and outcomes of the disease, shows a meta-analysis of individual patient data.
Supraventricular arrhythmias are common in patients with pulmonary arterial hypertension but can be successfully managed with standard treatments, a study shows.
Selexipag, alone or in combination with other classes of pulmonary arterial hypertension medication, reduced the composite rate of disease complications and deaths among patients in a phase III trial.
New blood biomarkers reflecting vasoreactivity in lung blood vessels of patients with heart- and lung disease, can lead to simplified diagnostics and better evaluation of treatment for patients with the condition pulmonary arterial hypertension (PAH).
Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine.
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.
The rate of myocardium glucose utilisation in the right ventricle correlates with its function and could be used to monitor treatment effects in patients with pulmonary arterial hypertension, findings indicate.
Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest.
Right atrial function is impaired in patients with pulmonary arterial hypertension and may indicate right ventricular overload and failure, research suggests.
The drug sildenafil, sold as Viagra and other brand names, improves insulin sensitivity in people at risk for diabetes, researchers at Vanderbilt University Medical Center reported today.
Researchers have identified the haemodynamic variables that best distinguish between patients with idiopathic pulmonary arterial hypertension and isolated post-capillary pulmonary hypertension.
Health-related quality of life is strongly associated with survival in patients with pulmonary arterial hypertension, making it a reasonable target for treatment, study findings suggest.
Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension.
The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.